Press releases
MGC Pharmaceuticals Releases CogniCann Phase II Clinical Trial Results
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to provide details of the results of its Phase II Clinical Trial into the effect of its proprietary Investigational Medicinal Product, CogniCann, an oral spray containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), on patients…